|
Accueil > Actualité
GSK: strategic collaboration with Wave Life Sciences
(CercleFinance.com) - GSK announces a strategic collaboration with Wave Life Sciences, a clinical-stage genetics company, to advance oligonucleotide therapies.
GSK says that oligonucleotides are short strands of DNA or RNA that can reduce, restore or modulate RNA through several different mechanisms. The research collaboration between the organisations is initially due to last four years. This will include combining GSK's knowledge with Wave's proprietary drug R&D platform, PRISMTM. The collaboration will enable GSK to advance up to eight programs by leveraging Wave's PRISM platform, and Wave to advance up to three programs by leveraging GSK's expertise in genetics and genomics. Under the terms of the agreement, Wave will receive an upfront payment of 170 million dollars, including 50 million dollars in stock. Copyright (c) 2022 CercleFinance.com. All rights reserved. |
19/04/2024 08:57
Veoliade fortes ambitions de croissance aux Etats-Unis 19/04/2024 08:42 Pluxeerelèvement des objectifs annuels 19/04/2024 08:18 Sodexohausse de 46% du résultat net ajusté au 1er semestre 19/04/2024 08:00 Spieacquisition d'ICG Group finalisée en Allemagne 19/04/2024 07:42 Argandividende versé à près de 28% en actions 19/04/2024 07:25 Mercialyshausse de 4,5% des loyers au 1er trimestre Tous les articles sociétés |
